The genomic landscape of GBM, as illustrated in Figure 4 and summarized in Table 2, is highly heterogeneous and includes mutations in key genes such as TP53, EGFR, and IDH1/2, which drive tumorigenesis and progression. The gene discussed is TP53; the disease is glioblastoma.